CD160 and B-cell chronic lymphocytic leukemia: Importantly the duration of ibrutinib therapy was not found to differ between patients who achieved PR compared to those reaching a CR (23.5 vs. 21 months, respectively; p = 0.924) and no difference was seen in expression of other inhibitory markers that are increased in patients with CLL (1) (CD244 (52 vs. 55%; p = 0.426), CD160 (25 vs. 23%; p = 0.326), or CTLA4 expression (3.05 vs. 2.55%; p = 0.622) (Figure 1B).